XENETIC BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
XENETIC BIOSCIENCES, INC. (XBIO) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $1.35 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2019-03-29
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2018 was $1.35M, a 24.23% decline from fiscal 2017.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2017 was $1.78M, a 7.18% decline from fiscal 2016.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2016 was $1.92M, a 14.82% decline from fiscal 2015.
- XENETIC BIOSCIENCES, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2015 was $2.26M, a 221.46% increase from fiscal 2014.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|
| 2018-12-31 | $1.35M 10-K · filed 2019-03-29 |
| 2017-12-31 | $1.78M 10-K · filed 2019-03-29 |
| 2016-12-31 | $1.92M 10-K · filed 2018-03-30 |
| 2015-12-31 | $2.26M 10-K · filed 2017-03-31 |
| 2014-12-31 | $702.04K 10-K · filed 2016-03-30 |
| 2013-12-31 | $431.50K 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |